Global SPECT and PET Diagnosis Radiopharmaceuticals Supply, Demand and Key Producers, 2026-2032
The global SPECT and PET Diagnosis Radiopharmaceuticals market size is expected to reach $ 9269 million by 2032, rising at a market growth of 6.7% CAGR during the forecast period (2026-2032).
SPECT and PET diagnosis radiopharmaceuticals refer to nuclear medicine diagnostic agents used in Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) imaging. These agents are typically formed by combining radioactive isotopes with biologically active molecules such as small compounds, peptides, or antibodies through chemical or biological conjugation. After administration, the radiopharmaceutical participates in specific physiological or biochemical processes in the body and emits detectable radiation signals that can be captured by imaging systems, enabling visualization of organ function, metabolic activity, and molecular-level biological changes. SPECT and PET radiopharmaceuticals are widely used in oncology diagnostics, cardiovascular evaluation, neurological disease detection, and the localization of infection or inflammation. They play a fundamental role in molecular imaging and precision medicine. With the development of targeted molecular probes and new radionuclides, these agents are evolving from traditional functional imaging toward early disease detection and molecular mechanism diagnostics, becoming an essential component of modern medical imaging systems.In 2025, global SPECT and PET diagnosis radiopharmaceutical production reached approximately X156.28 million Units and price is about 36.7USD/Unit.The average gross profit margin of this product is 65%.
With the rapid advancement of precision medicine and molecular imaging technologies, SPECT and PET diagnostic radiopharmaceuticals are becoming increasingly important in modern healthcare systems. The growing need for early diagnosis of cancer, neurological disorders, and cardiovascular diseases has significantly expanded the role of molecular imaging in clinical practice. Continuous development of targeted molecular probes and new radionuclides enables radiopharmaceuticals to more accurately reflect metabolic processes and molecular activities in the body, improving diagnostic sensitivity and specificity. In addition, the expansion of nuclear medicine centers, upgrades in medical imaging infrastructure, and the integration of diagnostic and therapeutic approaches are further accelerating the clinical adoption of SPECT and PET diagnostic agents.
Despite their high clinical value and technological sophistication, SPECT and PET diagnostic radiopharmaceuticals face several industry challenges. The development, production, and transportation of radioactive drugs require strict regulatory compliance related to nuclear safety and pharmaceutical quality control, which imposes high operational standards on manufacturers. Some critical radioisotopes have short half-lives, requiring reliable isotope supply systems and highly efficient logistics networks, which adds complexity to the supply chain. Additionally, the shortage of specialized nuclear medicine professionals and the uneven technical capabilities of medical institutions may affect the broader adoption and commercialization of these diagnostic agents.
In downstream medical applications, the role of SPECT and PET radiopharmaceuticals is gradually shifting from traditional organ function imaging toward molecular-level disease detection. PET imaging has become increasingly important for tumor staging, therapy response evaluation, and recurrence monitoring. Meanwhile, demand is growing in areas such as neurodegenerative diseases, inflammatory disorders, and immune-related conditions. With the development of personalized medicine, targeted diagnostic probes designed for specific biological markers are expanding, creating closer synergy between diagnostic imaging and targeted therapy. In the future, theranostic radiopharmaceuticals and companion diagnostics are expected to become key growth areas.
The upstream supply chain of SPECT and PET diagnostic radiopharmaceuticals mainly includes radioactive isotopes, chemical precursor molecules, and radiolabeling reagents. Commonly used radionuclides include technetium isotopes, fluorine isotopes, and iodine isotopes, which are typically produced through nuclear reactors or medical cyclotrons. Chemical precursor molecules serve as carriers that bind to radioactive isotopes to form specific molecular probes, and their structural design directly influences targeting capability and imaging performance. In addition, stable radiolabeling technologies and high-purity reagents are essential for ensuring the safety and imaging quality of these drugs. With the continuous evolution of nuclear medicine technologies, upstream materials are moving toward higher purity, better stability, and enhanced targeting efficiency.
This report studies the global SPECT and PET Diagnosis Radiopharmaceuticals production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for SPECT and PET Diagnosis Radiopharmaceuticals and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of SPECT and PET Diagnosis Radiopharmaceuticals that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global SPECT and PET Diagnosis Radiopharmaceuticals total production and demand, 2021-2032, (K Dose)
Global SPECT and PET Diagnosis Radiopharmaceuticals total production value, 2021-2032, (USD Million)
Global SPECT and PET Diagnosis Radiopharmaceuticals production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Dose), (based on production site)
Global SPECT and PET Diagnosis Radiopharmaceuticals consumption by region & country, CAGR, 2021-2032 & (K Dose)
U.S. VS China: SPECT and PET Diagnosis Radiopharmaceuticals domestic production, consumption, key domestic manufacturers and share
Global SPECT and PET Diagnosis Radiopharmaceuticals production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Dose)
Global SPECT and PET Diagnosis Radiopharmaceuticals production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Dose)
Global SPECT and PET Diagnosis Radiopharmaceuticals production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Dose)
This report profiles key players in the global SPECT and PET Diagnosis Radiopharmaceuticals market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Cardinal Health, GE Healthcare, Jubilant Pharma, Novartis, Curium Pharma, SIEMENS, Lantheus, Bracco Imaging, Eli Lilly, China Isotope & Radiation, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World SPECT and PET Diagnosis Radiopharmaceuticals market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Dose) and average price (US$/Dose) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global SPECT and PET Diagnosis Radiopharmaceuticals Market, By Region:
1. How big is the global SPECT and PET Diagnosis Radiopharmaceuticals market?
2. What is the demand of the global SPECT and PET Diagnosis Radiopharmaceuticals market?
3. What is the year over year growth of the global SPECT and PET Diagnosis Radiopharmaceuticals market?
4. What is the production and production value of the global SPECT and PET Diagnosis Radiopharmaceuticals market?
5. Who are the key producers in the global SPECT and PET Diagnosis Radiopharmaceuticals market?
6. What are the growth factors driving the market demand?
SPECT and PET diagnosis radiopharmaceuticals refer to nuclear medicine diagnostic agents used in Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) imaging. These agents are typically formed by combining radioactive isotopes with biologically active molecules such as small compounds, peptides, or antibodies through chemical or biological conjugation. After administration, the radiopharmaceutical participates in specific physiological or biochemical processes in the body and emits detectable radiation signals that can be captured by imaging systems, enabling visualization of organ function, metabolic activity, and molecular-level biological changes. SPECT and PET radiopharmaceuticals are widely used in oncology diagnostics, cardiovascular evaluation, neurological disease detection, and the localization of infection or inflammation. They play a fundamental role in molecular imaging and precision medicine. With the development of targeted molecular probes and new radionuclides, these agents are evolving from traditional functional imaging toward early disease detection and molecular mechanism diagnostics, becoming an essential component of modern medical imaging systems.In 2025, global SPECT and PET diagnosis radiopharmaceutical production reached approximately X156.28 million Units and price is about 36.7USD/Unit.The average gross profit margin of this product is 65%.
With the rapid advancement of precision medicine and molecular imaging technologies, SPECT and PET diagnostic radiopharmaceuticals are becoming increasingly important in modern healthcare systems. The growing need for early diagnosis of cancer, neurological disorders, and cardiovascular diseases has significantly expanded the role of molecular imaging in clinical practice. Continuous development of targeted molecular probes and new radionuclides enables radiopharmaceuticals to more accurately reflect metabolic processes and molecular activities in the body, improving diagnostic sensitivity and specificity. In addition, the expansion of nuclear medicine centers, upgrades in medical imaging infrastructure, and the integration of diagnostic and therapeutic approaches are further accelerating the clinical adoption of SPECT and PET diagnostic agents.
Despite their high clinical value and technological sophistication, SPECT and PET diagnostic radiopharmaceuticals face several industry challenges. The development, production, and transportation of radioactive drugs require strict regulatory compliance related to nuclear safety and pharmaceutical quality control, which imposes high operational standards on manufacturers. Some critical radioisotopes have short half-lives, requiring reliable isotope supply systems and highly efficient logistics networks, which adds complexity to the supply chain. Additionally, the shortage of specialized nuclear medicine professionals and the uneven technical capabilities of medical institutions may affect the broader adoption and commercialization of these diagnostic agents.
In downstream medical applications, the role of SPECT and PET radiopharmaceuticals is gradually shifting from traditional organ function imaging toward molecular-level disease detection. PET imaging has become increasingly important for tumor staging, therapy response evaluation, and recurrence monitoring. Meanwhile, demand is growing in areas such as neurodegenerative diseases, inflammatory disorders, and immune-related conditions. With the development of personalized medicine, targeted diagnostic probes designed for specific biological markers are expanding, creating closer synergy between diagnostic imaging and targeted therapy. In the future, theranostic radiopharmaceuticals and companion diagnostics are expected to become key growth areas.
The upstream supply chain of SPECT and PET diagnostic radiopharmaceuticals mainly includes radioactive isotopes, chemical precursor molecules, and radiolabeling reagents. Commonly used radionuclides include technetium isotopes, fluorine isotopes, and iodine isotopes, which are typically produced through nuclear reactors or medical cyclotrons. Chemical precursor molecules serve as carriers that bind to radioactive isotopes to form specific molecular probes, and their structural design directly influences targeting capability and imaging performance. In addition, stable radiolabeling technologies and high-purity reagents are essential for ensuring the safety and imaging quality of these drugs. With the continuous evolution of nuclear medicine technologies, upstream materials are moving toward higher purity, better stability, and enhanced targeting efficiency.
This report studies the global SPECT and PET Diagnosis Radiopharmaceuticals production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for SPECT and PET Diagnosis Radiopharmaceuticals and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of SPECT and PET Diagnosis Radiopharmaceuticals that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global SPECT and PET Diagnosis Radiopharmaceuticals total production and demand, 2021-2032, (K Dose)
Global SPECT and PET Diagnosis Radiopharmaceuticals total production value, 2021-2032, (USD Million)
Global SPECT and PET Diagnosis Radiopharmaceuticals production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Dose), (based on production site)
Global SPECT and PET Diagnosis Radiopharmaceuticals consumption by region & country, CAGR, 2021-2032 & (K Dose)
U.S. VS China: SPECT and PET Diagnosis Radiopharmaceuticals domestic production, consumption, key domestic manufacturers and share
Global SPECT and PET Diagnosis Radiopharmaceuticals production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Dose)
Global SPECT and PET Diagnosis Radiopharmaceuticals production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Dose)
Global SPECT and PET Diagnosis Radiopharmaceuticals production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Dose)
This report profiles key players in the global SPECT and PET Diagnosis Radiopharmaceuticals market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Cardinal Health, GE Healthcare, Jubilant Pharma, Novartis, Curium Pharma, SIEMENS, Lantheus, Bracco Imaging, Eli Lilly, China Isotope & Radiation, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World SPECT and PET Diagnosis Radiopharmaceuticals market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Dose) and average price (US$/Dose) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global SPECT and PET Diagnosis Radiopharmaceuticals Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Technetium 99
- Fluorine 18
- Other
- PET Imaging
- SPECT Imaging
- Hospitals
- Imaging Centers
- Other
- Oncology
- Cardiology
- Other
- Cardinal Health
- GE Healthcare
- Jubilant Pharma
- Novartis
- Curium Pharma
- SIEMENS
- Lantheus
- Bracco Imaging
- Eli Lilly
- China Isotope & Radiation
- Dongcheng
1. How big is the global SPECT and PET Diagnosis Radiopharmaceuticals market?
2. What is the demand of the global SPECT and PET Diagnosis Radiopharmaceuticals market?
3. What is the year over year growth of the global SPECT and PET Diagnosis Radiopharmaceuticals market?
4. What is the production and production value of the global SPECT and PET Diagnosis Radiopharmaceuticals market?
5. Who are the key producers in the global SPECT and PET Diagnosis Radiopharmaceuticals market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 SPECT and PET Diagnosis Radiopharmaceuticals Introduction
1.2 World SPECT and PET Diagnosis Radiopharmaceuticals Supply & Forecast
1.2.1 World SPECT and PET Diagnosis Radiopharmaceuticals Production Value (2021 & 2025 & 2032)
1.2.2 World SPECT and PET Diagnosis Radiopharmaceuticals Production (2021-2032)
1.2.3 World SPECT and PET Diagnosis Radiopharmaceuticals Pricing Trends (2021-2032)
1.3 World SPECT and PET Diagnosis Radiopharmaceuticals Production by Region (Based on Production Site)
1.3.1 World SPECT and PET Diagnosis Radiopharmaceuticals Production Value by Region (2021-2032)
1.3.2 World SPECT and PET Diagnosis Radiopharmaceuticals Production by Region (2021-2032)
1.3.3 World SPECT and PET Diagnosis Radiopharmaceuticals Average Price by Region (2021-2032)
1.3.4 North America SPECT and PET Diagnosis Radiopharmaceuticals Production (2021-2032)
1.3.5 Europe SPECT and PET Diagnosis Radiopharmaceuticals Production (2021-2032)
1.3.6 China SPECT and PET Diagnosis Radiopharmaceuticals Production (2021-2032)
1.3.7 Japan SPECT and PET Diagnosis Radiopharmaceuticals Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 SPECT and PET Diagnosis Radiopharmaceuticals Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 SPECT and PET Diagnosis Radiopharmaceuticals Major Market Trends
2 DEMAND SUMMARY
2.1 World SPECT and PET Diagnosis Radiopharmaceuticals Demand (2021-2032)
2.2 World SPECT and PET Diagnosis Radiopharmaceuticals Consumption by Region
2.2.1 World SPECT and PET Diagnosis Radiopharmaceuticals Consumption by Region (2021-2026)
2.2.2 World SPECT and PET Diagnosis Radiopharmaceuticals Consumption Forecast by Region (2027-2032)
2.3 United States SPECT and PET Diagnosis Radiopharmaceuticals Consumption (2021-2032)
2.4 China SPECT and PET Diagnosis Radiopharmaceuticals Consumption (2021-2032)
2.5 Europe SPECT and PET Diagnosis Radiopharmaceuticals Consumption (2021-2032)
2.6 Japan SPECT and PET Diagnosis Radiopharmaceuticals Consumption (2021-2032)
2.7 South Korea SPECT and PET Diagnosis Radiopharmaceuticals Consumption (2021-2032)
2.8 ASEAN SPECT and PET Diagnosis Radiopharmaceuticals Consumption (2021-2032)
2.9 India SPECT and PET Diagnosis Radiopharmaceuticals Consumption (2021-2032)
3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World SPECT and PET Diagnosis Radiopharmaceuticals Production Value by Manufacturer (2021-2026)
3.2 World SPECT and PET Diagnosis Radiopharmaceuticals Production by Manufacturer (2021-2026)
3.3 World SPECT and PET Diagnosis Radiopharmaceuticals Average Price by Manufacturer (2021-2026)
3.4 SPECT and PET Diagnosis Radiopharmaceuticals Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global SPECT and PET Diagnosis Radiopharmaceuticals Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for SPECT and PET Diagnosis Radiopharmaceuticals in 2025
3.5.3 Global Concentration Ratios (CR8) for SPECT and PET Diagnosis Radiopharmaceuticals in 2025
3.6 SPECT and PET Diagnosis Radiopharmaceuticals Market: Overall Company Footprint Analysis
3.6.1 SPECT and PET Diagnosis Radiopharmaceuticals Market: Region Footprint
3.6.2 SPECT and PET Diagnosis Radiopharmaceuticals Market: Company Product Type Footprint
3.6.3 SPECT and PET Diagnosis Radiopharmaceuticals Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: SPECT and PET Diagnosis Radiopharmaceuticals Production Value Comparison
4.1.1 United States VS China: SPECT and PET Diagnosis Radiopharmaceuticals Production Value Comparison (2021 & 2025 & 2032)
4.1.2 United States VS China: SPECT and PET Diagnosis Radiopharmaceuticals Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: SPECT and PET Diagnosis Radiopharmaceuticals Production Comparison
4.2.1 United States VS China: SPECT and PET Diagnosis Radiopharmaceuticals Production Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: SPECT and PET Diagnosis Radiopharmaceuticals Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: SPECT and PET Diagnosis Radiopharmaceuticals Consumption Comparison
4.3.1 United States VS China: SPECT and PET Diagnosis Radiopharmaceuticals Consumption Comparison (2021 & 2025 & 2032)
4.3.2 United States VS China: SPECT and PET Diagnosis Radiopharmaceuticals Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based SPECT and PET Diagnosis Radiopharmaceuticals Manufacturers and Market Share, 2021-2026
4.4.1 United States Based SPECT and PET Diagnosis Radiopharmaceuticals Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers SPECT and PET Diagnosis Radiopharmaceuticals Production Value (2021-2026)
4.4.3 United States Based Manufacturers SPECT and PET Diagnosis Radiopharmaceuticals Production (2021-2026)
4.5 China Based SPECT and PET Diagnosis Radiopharmaceuticals Manufacturers and Market Share
4.5.1 China Based SPECT and PET Diagnosis Radiopharmaceuticals Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers SPECT and PET Diagnosis Radiopharmaceuticals Production Value (2021-2026)
4.5.3 China Based Manufacturers SPECT and PET Diagnosis Radiopharmaceuticals Production (2021-2026)
4.6 Rest of World Based SPECT and PET Diagnosis Radiopharmaceuticals Manufacturers and Market Share, 2021-2026
4.6.1 Rest of World Based SPECT and PET Diagnosis Radiopharmaceuticals Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers SPECT and PET Diagnosis Radiopharmaceuticals Production Value (2021-2026)
4.6.3 Rest of World Based Manufacturers SPECT and PET Diagnosis Radiopharmaceuticals Production (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World SPECT and PET Diagnosis Radiopharmaceuticals Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Technetium
5.2.2 Fluorine
5.2.3 Other
5.3 Market Segment by Type
5.3.1 World SPECT and PET Diagnosis Radiopharmaceuticals Production by Type (2021-2032)
5.3.2 World SPECT and PET Diagnosis Radiopharmaceuticals Production Value by Type (2021-2032)
5.3.3 World SPECT and PET Diagnosis Radiopharmaceuticals Average Price by Type (2021-2032)
6 MARKET ANALYSIS BY IMAGING MODALITY
6.1 World SPECT and PET Diagnosis Radiopharmaceuticals Market Size Overview by Imaging Modality: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Imaging Modality
6.2.1 PET Imaging
6.2.2 SPECT Imaging
6.3 Market Segment by Imaging Modality
6.3.1 World SPECT and PET Diagnosis Radiopharmaceuticals Production by Imaging Modality (2021-2032)
6.3.2 World SPECT and PET Diagnosis Radiopharmaceuticals Production Value by Imaging Modality (2021-2032)
6.3.3 World SPECT and PET Diagnosis Radiopharmaceuticals Average Price by Imaging Modality (2021-2032)
7 MARKET ANALYSIS BY END USER
7.1 World SPECT and PET Diagnosis Radiopharmaceuticals Market Size Overview by End User: 2021 VS 2025 VS 2032
7.2 Segment Introduction by End User
7.2.1 Hospitals
7.2.2 Imaging Centers
7.2.3 Other
7.3 Market Segment by End User
7.3.1 World SPECT and PET Diagnosis Radiopharmaceuticals Production by End User (2021-2032)
7.3.2 World SPECT and PET Diagnosis Radiopharmaceuticals Production Value by End User (2021-2032)
7.3.3 World SPECT and PET Diagnosis Radiopharmaceuticals Average Price by End User (2021-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World SPECT and PET Diagnosis Radiopharmaceuticals Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Oncology
8.2.2 Cardiology
8.2.3 Other
8.3 Market Segment by Application
8.3.1 World SPECT and PET Diagnosis Radiopharmaceuticals Production by Application (2021-2032)
8.3.2 World SPECT and PET Diagnosis Radiopharmaceuticals Production Value by Application (2021-2032)
8.3.3 World SPECT and PET Diagnosis Radiopharmaceuticals Average Price by Application (2021-2032)
9 COMPANY PROFILES
9.1 Cardinal Health
9.1.1 Cardinal Health Details
9.1.2 Cardinal Health Major Business
9.1.3 Cardinal Health SPECT and PET Diagnosis Radiopharmaceuticals Product and Services
9.1.4 Cardinal Health SPECT and PET Diagnosis Radiopharmaceuticals Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.1.5 Cardinal Health Recent Developments/Updates
9.1.6 Cardinal Health Competitive Strengths & Weaknesses
9.2 GE Healthcare
9.2.1 GE Healthcare Details
9.2.2 GE Healthcare Major Business
9.2.3 GE Healthcare SPECT and PET Diagnosis Radiopharmaceuticals Product and Services
9.2.4 GE Healthcare SPECT and PET Diagnosis Radiopharmaceuticals Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.2.5 GE Healthcare Recent Developments/Updates
9.2.6 GE Healthcare Competitive Strengths & Weaknesses
9.3 Jubilant Pharma
9.3.1 Jubilant Pharma Details
9.3.2 Jubilant Pharma Major Business
9.3.3 Jubilant Pharma SPECT and PET Diagnosis Radiopharmaceuticals Product and Services
9.3.4 Jubilant Pharma SPECT and PET Diagnosis Radiopharmaceuticals Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.3.5 Jubilant Pharma Recent Developments/Updates
9.3.6 Jubilant Pharma Competitive Strengths & Weaknesses
9.4 Novartis
9.4.1 Novartis Details
9.4.2 Novartis Major Business
9.4.3 Novartis SPECT and PET Diagnosis Radiopharmaceuticals Product and Services
9.4.4 Novartis SPECT and PET Diagnosis Radiopharmaceuticals Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.4.5 Novartis Recent Developments/Updates
9.4.6 Novartis Competitive Strengths & Weaknesses
9.5 Curium Pharma
9.5.1 Curium Pharma Details
9.5.2 Curium Pharma Major Business
9.5.3 Curium Pharma SPECT and PET Diagnosis Radiopharmaceuticals Product and Services
9.5.4 Curium Pharma SPECT and PET Diagnosis Radiopharmaceuticals Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.5.5 Curium Pharma Recent Developments/Updates
9.5.6 Curium Pharma Competitive Strengths & Weaknesses
9.6 SIEMENS
9.6.1 SIEMENS Details
9.6.2 SIEMENS Major Business
9.6.3 SIEMENS SPECT and PET Diagnosis Radiopharmaceuticals Product and Services
9.6.4 SIEMENS SPECT and PET Diagnosis Radiopharmaceuticals Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.6.5 SIEMENS Recent Developments/Updates
9.6.6 SIEMENS Competitive Strengths & Weaknesses
9.7 Lantheus
9.7.1 Lantheus Details
9.7.2 Lantheus Major Business
9.7.3 Lantheus SPECT and PET Diagnosis Radiopharmaceuticals Product and Services
9.7.4 Lantheus SPECT and PET Diagnosis Radiopharmaceuticals Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.7.5 Lantheus Recent Developments/Updates
9.7.6 Lantheus Competitive Strengths & Weaknesses
9.8 Bracco Imaging
9.8.1 Bracco Imaging Details
9.8.2 Bracco Imaging Major Business
9.8.3 Bracco Imaging SPECT and PET Diagnosis Radiopharmaceuticals Product and Services
9.8.4 Bracco Imaging SPECT and PET Diagnosis Radiopharmaceuticals Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.8.5 Bracco Imaging Recent Developments/Updates
9.8.6 Bracco Imaging Competitive Strengths & Weaknesses
9.9 Eli Lilly
9.9.1 Eli Lilly Details
9.9.2 Eli Lilly Major Business
9.9.3 Eli Lilly SPECT and PET Diagnosis Radiopharmaceuticals Product and Services
9.9.4 Eli Lilly SPECT and PET Diagnosis Radiopharmaceuticals Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.9.5 Eli Lilly Recent Developments/Updates
9.9.6 Eli Lilly Competitive Strengths & Weaknesses
9.10 China Isotope & Radiation
9.10.1 China Isotope & Radiation Details
9.10.2 China Isotope & Radiation Major Business
9.10.3 China Isotope & Radiation SPECT and PET Diagnosis Radiopharmaceuticals Product and Services
9.10.4 China Isotope & Radiation SPECT and PET Diagnosis Radiopharmaceuticals Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.10.5 China Isotope & Radiation Recent Developments/Updates
9.10.6 China Isotope & Radiation Competitive Strengths & Weaknesses
9.11 Dongcheng
9.11.1 Dongcheng Details
9.11.2 Dongcheng Major Business
9.11.3 Dongcheng SPECT and PET Diagnosis Radiopharmaceuticals Product and Services
9.11.4 Dongcheng SPECT and PET Diagnosis Radiopharmaceuticals Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.11.5 Dongcheng Recent Developments/Updates
9.11.6 Dongcheng Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 SPECT and PET Diagnosis Radiopharmaceuticals Industry Chain
10.2 SPECT and PET Diagnosis Radiopharmaceuticals Upstream Analysis
10.2.1 SPECT and PET Diagnosis Radiopharmaceuticals Core Raw Materials
10.2.2 Main Manufacturers of SPECT and PET Diagnosis Radiopharmaceuticals Core Raw Materials
10.3 Midstream Analysis
10.4 Downstream Analysis
10.5 SPECT and PET Diagnosis Radiopharmaceuticals Production Mode
10.6 SPECT and PET Diagnosis Radiopharmaceuticals Procurement Model
10.7 SPECT and PET Diagnosis Radiopharmaceuticals Industry Sales Model and Sales Channels
10.7.1 SPECT and PET Diagnosis Radiopharmaceuticals Sales Model
10.7.2 SPECT and PET Diagnosis Radiopharmaceuticals Typical Distributors
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
1.1 SPECT and PET Diagnosis Radiopharmaceuticals Introduction
1.2 World SPECT and PET Diagnosis Radiopharmaceuticals Supply & Forecast
1.2.1 World SPECT and PET Diagnosis Radiopharmaceuticals Production Value (2021 & 2025 & 2032)
1.2.2 World SPECT and PET Diagnosis Radiopharmaceuticals Production (2021-2032)
1.2.3 World SPECT and PET Diagnosis Radiopharmaceuticals Pricing Trends (2021-2032)
1.3 World SPECT and PET Diagnosis Radiopharmaceuticals Production by Region (Based on Production Site)
1.3.1 World SPECT and PET Diagnosis Radiopharmaceuticals Production Value by Region (2021-2032)
1.3.2 World SPECT and PET Diagnosis Radiopharmaceuticals Production by Region (2021-2032)
1.3.3 World SPECT and PET Diagnosis Radiopharmaceuticals Average Price by Region (2021-2032)
1.3.4 North America SPECT and PET Diagnosis Radiopharmaceuticals Production (2021-2032)
1.3.5 Europe SPECT and PET Diagnosis Radiopharmaceuticals Production (2021-2032)
1.3.6 China SPECT and PET Diagnosis Radiopharmaceuticals Production (2021-2032)
1.3.7 Japan SPECT and PET Diagnosis Radiopharmaceuticals Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 SPECT and PET Diagnosis Radiopharmaceuticals Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 SPECT and PET Diagnosis Radiopharmaceuticals Major Market Trends
2 DEMAND SUMMARY
2.1 World SPECT and PET Diagnosis Radiopharmaceuticals Demand (2021-2032)
2.2 World SPECT and PET Diagnosis Radiopharmaceuticals Consumption by Region
2.2.1 World SPECT and PET Diagnosis Radiopharmaceuticals Consumption by Region (2021-2026)
2.2.2 World SPECT and PET Diagnosis Radiopharmaceuticals Consumption Forecast by Region (2027-2032)
2.3 United States SPECT and PET Diagnosis Radiopharmaceuticals Consumption (2021-2032)
2.4 China SPECT and PET Diagnosis Radiopharmaceuticals Consumption (2021-2032)
2.5 Europe SPECT and PET Diagnosis Radiopharmaceuticals Consumption (2021-2032)
2.6 Japan SPECT and PET Diagnosis Radiopharmaceuticals Consumption (2021-2032)
2.7 South Korea SPECT and PET Diagnosis Radiopharmaceuticals Consumption (2021-2032)
2.8 ASEAN SPECT and PET Diagnosis Radiopharmaceuticals Consumption (2021-2032)
2.9 India SPECT and PET Diagnosis Radiopharmaceuticals Consumption (2021-2032)
3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World SPECT and PET Diagnosis Radiopharmaceuticals Production Value by Manufacturer (2021-2026)
3.2 World SPECT and PET Diagnosis Radiopharmaceuticals Production by Manufacturer (2021-2026)
3.3 World SPECT and PET Diagnosis Radiopharmaceuticals Average Price by Manufacturer (2021-2026)
3.4 SPECT and PET Diagnosis Radiopharmaceuticals Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global SPECT and PET Diagnosis Radiopharmaceuticals Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for SPECT and PET Diagnosis Radiopharmaceuticals in 2025
3.5.3 Global Concentration Ratios (CR8) for SPECT and PET Diagnosis Radiopharmaceuticals in 2025
3.6 SPECT and PET Diagnosis Radiopharmaceuticals Market: Overall Company Footprint Analysis
3.6.1 SPECT and PET Diagnosis Radiopharmaceuticals Market: Region Footprint
3.6.2 SPECT and PET Diagnosis Radiopharmaceuticals Market: Company Product Type Footprint
3.6.3 SPECT and PET Diagnosis Radiopharmaceuticals Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: SPECT and PET Diagnosis Radiopharmaceuticals Production Value Comparison
4.1.1 United States VS China: SPECT and PET Diagnosis Radiopharmaceuticals Production Value Comparison (2021 & 2025 & 2032)
4.1.2 United States VS China: SPECT and PET Diagnosis Radiopharmaceuticals Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: SPECT and PET Diagnosis Radiopharmaceuticals Production Comparison
4.2.1 United States VS China: SPECT and PET Diagnosis Radiopharmaceuticals Production Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: SPECT and PET Diagnosis Radiopharmaceuticals Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: SPECT and PET Diagnosis Radiopharmaceuticals Consumption Comparison
4.3.1 United States VS China: SPECT and PET Diagnosis Radiopharmaceuticals Consumption Comparison (2021 & 2025 & 2032)
4.3.2 United States VS China: SPECT and PET Diagnosis Radiopharmaceuticals Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based SPECT and PET Diagnosis Radiopharmaceuticals Manufacturers and Market Share, 2021-2026
4.4.1 United States Based SPECT and PET Diagnosis Radiopharmaceuticals Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers SPECT and PET Diagnosis Radiopharmaceuticals Production Value (2021-2026)
4.4.3 United States Based Manufacturers SPECT and PET Diagnosis Radiopharmaceuticals Production (2021-2026)
4.5 China Based SPECT and PET Diagnosis Radiopharmaceuticals Manufacturers and Market Share
4.5.1 China Based SPECT and PET Diagnosis Radiopharmaceuticals Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers SPECT and PET Diagnosis Radiopharmaceuticals Production Value (2021-2026)
4.5.3 China Based Manufacturers SPECT and PET Diagnosis Radiopharmaceuticals Production (2021-2026)
4.6 Rest of World Based SPECT and PET Diagnosis Radiopharmaceuticals Manufacturers and Market Share, 2021-2026
4.6.1 Rest of World Based SPECT and PET Diagnosis Radiopharmaceuticals Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers SPECT and PET Diagnosis Radiopharmaceuticals Production Value (2021-2026)
4.6.3 Rest of World Based Manufacturers SPECT and PET Diagnosis Radiopharmaceuticals Production (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World SPECT and PET Diagnosis Radiopharmaceuticals Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Technetium
5.2.2 Fluorine
5.2.3 Other
5.3 Market Segment by Type
5.3.1 World SPECT and PET Diagnosis Radiopharmaceuticals Production by Type (2021-2032)
5.3.2 World SPECT and PET Diagnosis Radiopharmaceuticals Production Value by Type (2021-2032)
5.3.3 World SPECT and PET Diagnosis Radiopharmaceuticals Average Price by Type (2021-2032)
6 MARKET ANALYSIS BY IMAGING MODALITY
6.1 World SPECT and PET Diagnosis Radiopharmaceuticals Market Size Overview by Imaging Modality: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Imaging Modality
6.2.1 PET Imaging
6.2.2 SPECT Imaging
6.3 Market Segment by Imaging Modality
6.3.1 World SPECT and PET Diagnosis Radiopharmaceuticals Production by Imaging Modality (2021-2032)
6.3.2 World SPECT and PET Diagnosis Radiopharmaceuticals Production Value by Imaging Modality (2021-2032)
6.3.3 World SPECT and PET Diagnosis Radiopharmaceuticals Average Price by Imaging Modality (2021-2032)
7 MARKET ANALYSIS BY END USER
7.1 World SPECT and PET Diagnosis Radiopharmaceuticals Market Size Overview by End User: 2021 VS 2025 VS 2032
7.2 Segment Introduction by End User
7.2.1 Hospitals
7.2.2 Imaging Centers
7.2.3 Other
7.3 Market Segment by End User
7.3.1 World SPECT and PET Diagnosis Radiopharmaceuticals Production by End User (2021-2032)
7.3.2 World SPECT and PET Diagnosis Radiopharmaceuticals Production Value by End User (2021-2032)
7.3.3 World SPECT and PET Diagnosis Radiopharmaceuticals Average Price by End User (2021-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World SPECT and PET Diagnosis Radiopharmaceuticals Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Oncology
8.2.2 Cardiology
8.2.3 Other
8.3 Market Segment by Application
8.3.1 World SPECT and PET Diagnosis Radiopharmaceuticals Production by Application (2021-2032)
8.3.2 World SPECT and PET Diagnosis Radiopharmaceuticals Production Value by Application (2021-2032)
8.3.3 World SPECT and PET Diagnosis Radiopharmaceuticals Average Price by Application (2021-2032)
9 COMPANY PROFILES
9.1 Cardinal Health
9.1.1 Cardinal Health Details
9.1.2 Cardinal Health Major Business
9.1.3 Cardinal Health SPECT and PET Diagnosis Radiopharmaceuticals Product and Services
9.1.4 Cardinal Health SPECT and PET Diagnosis Radiopharmaceuticals Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.1.5 Cardinal Health Recent Developments/Updates
9.1.6 Cardinal Health Competitive Strengths & Weaknesses
9.2 GE Healthcare
9.2.1 GE Healthcare Details
9.2.2 GE Healthcare Major Business
9.2.3 GE Healthcare SPECT and PET Diagnosis Radiopharmaceuticals Product and Services
9.2.4 GE Healthcare SPECT and PET Diagnosis Radiopharmaceuticals Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.2.5 GE Healthcare Recent Developments/Updates
9.2.6 GE Healthcare Competitive Strengths & Weaknesses
9.3 Jubilant Pharma
9.3.1 Jubilant Pharma Details
9.3.2 Jubilant Pharma Major Business
9.3.3 Jubilant Pharma SPECT and PET Diagnosis Radiopharmaceuticals Product and Services
9.3.4 Jubilant Pharma SPECT and PET Diagnosis Radiopharmaceuticals Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.3.5 Jubilant Pharma Recent Developments/Updates
9.3.6 Jubilant Pharma Competitive Strengths & Weaknesses
9.4 Novartis
9.4.1 Novartis Details
9.4.2 Novartis Major Business
9.4.3 Novartis SPECT and PET Diagnosis Radiopharmaceuticals Product and Services
9.4.4 Novartis SPECT and PET Diagnosis Radiopharmaceuticals Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.4.5 Novartis Recent Developments/Updates
9.4.6 Novartis Competitive Strengths & Weaknesses
9.5 Curium Pharma
9.5.1 Curium Pharma Details
9.5.2 Curium Pharma Major Business
9.5.3 Curium Pharma SPECT and PET Diagnosis Radiopharmaceuticals Product and Services
9.5.4 Curium Pharma SPECT and PET Diagnosis Radiopharmaceuticals Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.5.5 Curium Pharma Recent Developments/Updates
9.5.6 Curium Pharma Competitive Strengths & Weaknesses
9.6 SIEMENS
9.6.1 SIEMENS Details
9.6.2 SIEMENS Major Business
9.6.3 SIEMENS SPECT and PET Diagnosis Radiopharmaceuticals Product and Services
9.6.4 SIEMENS SPECT and PET Diagnosis Radiopharmaceuticals Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.6.5 SIEMENS Recent Developments/Updates
9.6.6 SIEMENS Competitive Strengths & Weaknesses
9.7 Lantheus
9.7.1 Lantheus Details
9.7.2 Lantheus Major Business
9.7.3 Lantheus SPECT and PET Diagnosis Radiopharmaceuticals Product and Services
9.7.4 Lantheus SPECT and PET Diagnosis Radiopharmaceuticals Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.7.5 Lantheus Recent Developments/Updates
9.7.6 Lantheus Competitive Strengths & Weaknesses
9.8 Bracco Imaging
9.8.1 Bracco Imaging Details
9.8.2 Bracco Imaging Major Business
9.8.3 Bracco Imaging SPECT and PET Diagnosis Radiopharmaceuticals Product and Services
9.8.4 Bracco Imaging SPECT and PET Diagnosis Radiopharmaceuticals Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.8.5 Bracco Imaging Recent Developments/Updates
9.8.6 Bracco Imaging Competitive Strengths & Weaknesses
9.9 Eli Lilly
9.9.1 Eli Lilly Details
9.9.2 Eli Lilly Major Business
9.9.3 Eli Lilly SPECT and PET Diagnosis Radiopharmaceuticals Product and Services
9.9.4 Eli Lilly SPECT and PET Diagnosis Radiopharmaceuticals Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.9.5 Eli Lilly Recent Developments/Updates
9.9.6 Eli Lilly Competitive Strengths & Weaknesses
9.10 China Isotope & Radiation
9.10.1 China Isotope & Radiation Details
9.10.2 China Isotope & Radiation Major Business
9.10.3 China Isotope & Radiation SPECT and PET Diagnosis Radiopharmaceuticals Product and Services
9.10.4 China Isotope & Radiation SPECT and PET Diagnosis Radiopharmaceuticals Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.10.5 China Isotope & Radiation Recent Developments/Updates
9.10.6 China Isotope & Radiation Competitive Strengths & Weaknesses
9.11 Dongcheng
9.11.1 Dongcheng Details
9.11.2 Dongcheng Major Business
9.11.3 Dongcheng SPECT and PET Diagnosis Radiopharmaceuticals Product and Services
9.11.4 Dongcheng SPECT and PET Diagnosis Radiopharmaceuticals Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.11.5 Dongcheng Recent Developments/Updates
9.11.6 Dongcheng Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 SPECT and PET Diagnosis Radiopharmaceuticals Industry Chain
10.2 SPECT and PET Diagnosis Radiopharmaceuticals Upstream Analysis
10.2.1 SPECT and PET Diagnosis Radiopharmaceuticals Core Raw Materials
10.2.2 Main Manufacturers of SPECT and PET Diagnosis Radiopharmaceuticals Core Raw Materials
10.3 Midstream Analysis
10.4 Downstream Analysis
10.5 SPECT and PET Diagnosis Radiopharmaceuticals Production Mode
10.6 SPECT and PET Diagnosis Radiopharmaceuticals Procurement Model
10.7 SPECT and PET Diagnosis Radiopharmaceuticals Industry Sales Model and Sales Channels
10.7.1 SPECT and PET Diagnosis Radiopharmaceuticals Sales Model
10.7.2 SPECT and PET Diagnosis Radiopharmaceuticals Typical Distributors
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
LIST OF TABLES
Table 1. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value by Region (2021, 2025 and 2032) & (USD Million)
Table 2. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value by Region (2021-2026) & (USD Million)
Table 3. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value by Region (2027-2032) & (USD Million)
Table 4. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value Market Share by Region (2021-2026)
Table 5. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value Market Share by Region (2027-2032)
Table 6. World SPECT and PET Diagnosis Radiopharmaceuticals Production by Region (2021-2026) & (K Dose)
Table 7. World SPECT and PET Diagnosis Radiopharmaceuticals Production by Region (2027-2032) & (K Dose)
Table 8. World SPECT and PET Diagnosis Radiopharmaceuticals Production Market Share by Region (2021-2026)
Table 9. World SPECT and PET Diagnosis Radiopharmaceuticals Production Market Share by Region (2027-2032)
Table 10. World SPECT and PET Diagnosis Radiopharmaceuticals Average Price by Region (2021-2026) & (US$/Dose)
Table 11. World SPECT and PET Diagnosis Radiopharmaceuticals Average Price by Region (2027-2032) & (US$/Dose)
Table 12. SPECT and PET Diagnosis Radiopharmaceuticals Major Market Trends
Table 13. World SPECT and PET Diagnosis Radiopharmaceuticals Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (K Dose)
Table 14. World SPECT and PET Diagnosis Radiopharmaceuticals Consumption by Region (2021-2026) & (K Dose)
Table 15. World SPECT and PET Diagnosis Radiopharmaceuticals Consumption Forecast by Region (2027-2032) & (K Dose)
Table 16. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value by Manufacturer (2021-2026) & (USD Million)
Table 17. Production Value Market Share of Key SPECT and PET Diagnosis Radiopharmaceuticals Producers in 2025
Table 18. World SPECT and PET Diagnosis Radiopharmaceuticals Production by Manufacturer (2021-2026) & (K Dose)
Table 19. Production Market Share of Key SPECT and PET Diagnosis Radiopharmaceuticals Producers in 2025
Table 20. World SPECT and PET Diagnosis Radiopharmaceuticals Average Price by Manufacturer (2021-2026) & (US$/Dose)
Table 21. Global SPECT and PET Diagnosis Radiopharmaceuticals Company Evaluation Quadrant
Table 22. World SPECT and PET Diagnosis Radiopharmaceuticals Industry Rank of Major Manufacturers, Based on Production Value in 2025
Table 23. Head Office and SPECT and PET Diagnosis Radiopharmaceuticals Production Site of Key Manufacturer
Table 24. SPECT and PET Diagnosis Radiopharmaceuticals Market: Company Product Type Footprint
Table 25. SPECT and PET Diagnosis Radiopharmaceuticals Market: Company Product Application Footprint
Table 26. SPECT and PET Diagnosis Radiopharmaceuticals Competitive Factors
Table 27. SPECT and PET Diagnosis Radiopharmaceuticals New Entrant and Capacity Expansion Plans
Table 28. SPECT and PET Diagnosis Radiopharmaceuticals Mergers & Acquisitions Activity
Table 29. United States VS China SPECT and PET Diagnosis Radiopharmaceuticals Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 30. United States VS China SPECT and PET Diagnosis Radiopharmaceuticals Production Comparison, (2021 & 2025 & 2032) & (K Dose)
Table 31. United States VS China SPECT and PET Diagnosis Radiopharmaceuticals Consumption Comparison, (2021 & 2025 & 2032) & (K Dose)
Table 32. United States Based SPECT and PET Diagnosis Radiopharmaceuticals Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers SPECT and PET Diagnosis Radiopharmaceuticals Production Value, (2021-2026) & (USD Million)
Table 34. United States Based Manufacturers SPECT and PET Diagnosis Radiopharmaceuticals Production Value Market Share (2021-2026)
Table 35. United States Based Manufacturers SPECT and PET Diagnosis Radiopharmaceuticals Production (2021-2026) & (K Dose)
Table 36. United States Based Manufacturers SPECT and PET Diagnosis Radiopharmaceuticals Production Market Share (2021-2026)
Table 37. China Based SPECT and PET Diagnosis Radiopharmaceuticals Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers SPECT and PET Diagnosis Radiopharmaceuticals Production Value, (2021-2026) & (USD Million)
Table 39. China Based Manufacturers SPECT and PET Diagnosis Radiopharmaceuticals Production Value Market Share (2021-2026)
Table 40. China Based Manufacturers SPECT and PET Diagnosis Radiopharmaceuticals Production, (2021-2026) & (K Dose)
Table 41. China Based Manufacturers SPECT and PET Diagnosis Radiopharmaceuticals Production Market Share (2021-2026)
Table 42. Rest of World Based SPECT and PET Diagnosis Radiopharmaceuticals Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers SPECT and PET Diagnosis Radiopharmaceuticals Production Value, (2021-2026) & (USD Million)
Table 44. Rest of World Based Manufacturers SPECT and PET Diagnosis Radiopharmaceuticals Production Value Market Share (2021-2026)
Table 45. Rest of World Based Manufacturers SPECT and PET Diagnosis Radiopharmaceuticals Production, (2021-2026) & (K Dose)
Table 46. Rest of World Based Manufacturers SPECT and PET Diagnosis Radiopharmaceuticals Production Market Share (2021-2026)
Table 47. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value by Type, (USD Million), 2021 & 2025 & 2032
Table 48. World SPECT and PET Diagnosis Radiopharmaceuticals Production by Type (2021-2026) & (K Dose)
Table 49. World SPECT and PET Diagnosis Radiopharmaceuticals Production by Type (2027-2032) & (K Dose)
Table 50. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value by Type (2021-2026) & (USD Million)
Table 51. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value by Type (2027-2032) & (USD Million)
Table 52. World SPECT and PET Diagnosis Radiopharmaceuticals Average Price by Type (2021-2026) & (US$/Dose)
Table 53. World SPECT and PET Diagnosis Radiopharmaceuticals Average Price by Type (2027-2032) & (US$/Dose)
Table 54. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value by Imaging Modality, (USD Million), 2021 & 2025 & 2032
Table 55. World SPECT and PET Diagnosis Radiopharmaceuticals Production by Imaging Modality (2021-2026) & (K Dose)
Table 56. World SPECT and PET Diagnosis Radiopharmaceuticals Production by Imaging Modality (2027-2032) & (K Dose)
Table 57. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value by Imaging Modality (2021-2026) & (USD Million)
Table 58. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value by Imaging Modality (2027-2032) & (USD Million)
Table 59. World SPECT and PET Diagnosis Radiopharmaceuticals Average Price by Imaging Modality (2021-2026) & (US$/Dose)
Table 60. World SPECT and PET Diagnosis Radiopharmaceuticals Average Price by Imaging Modality (2027-2032) & (US$/Dose)
Table 61. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value by End User, (USD Million), 2021 & 2025 & 2032
Table 62. World SPECT and PET Diagnosis Radiopharmaceuticals Production by End User (2021-2026) & (K Dose)
Table 63. World SPECT and PET Diagnosis Radiopharmaceuticals Production by End User (2027-2032) & (K Dose)
Table 64. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value by End User (2021-2026) & (USD Million)
Table 65. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value by End User (2027-2032) & (USD Million)
Table 66. World SPECT and PET Diagnosis Radiopharmaceuticals Average Price by End User (2021-2026) & (US$/Dose)
Table 67. World SPECT and PET Diagnosis Radiopharmaceuticals Average Price by End User (2027-2032) & (US$/Dose)
Table 68. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value by Application, (USD Million), 2021 & 2025 & 2032
Table 69. World SPECT and PET Diagnosis Radiopharmaceuticals Production by Application (2021-2026) & (K Dose)
Table 70. World SPECT and PET Diagnosis Radiopharmaceuticals Production by Application (2027-2032) & (K Dose)
Table 71. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value by Application (2021-2026) & (USD Million)
Table 72. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value by Application (2027-2032) & (USD Million)
Table 73. World SPECT and PET Diagnosis Radiopharmaceuticals Average Price by Application (2021-2026) & (US$/Dose)
Table 74. World SPECT and PET Diagnosis Radiopharmaceuticals Average Price by Application (2027-2032) & (US$/Dose)
Table 75. Cardinal Health Basic Information, Manufacturing Base and Competitors
Table 76. Cardinal Health Major Business
Table 77. Cardinal Health SPECT and PET Diagnosis Radiopharmaceuticals Product and Services
Table 78. Cardinal Health SPECT and PET Diagnosis Radiopharmaceuticals Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 79. Cardinal Health Recent Developments/Updates
Table 80. Cardinal Health Competitive Strengths & Weaknesses
Table 81. GE Healthcare Basic Information, Manufacturing Base and Competitors
Table 82. GE Healthcare Major Business
Table 83. GE Healthcare SPECT and PET Diagnosis Radiopharmaceuticals Product and Services
Table 84. GE Healthcare SPECT and PET Diagnosis Radiopharmaceuticals Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 85. GE Healthcare Recent Developments/Updates
Table 86. GE Healthcare Competitive Strengths & Weaknesses
Table 87. Jubilant Pharma Basic Information, Manufacturing Base and Competitors
Table 88. Jubilant Pharma Major Business
Table 89. Jubilant Pharma SPECT and PET Diagnosis Radiopharmaceuticals Product and Services
Table 90. Jubilant Pharma SPECT and PET Diagnosis Radiopharmaceuticals Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 91. Jubilant Pharma Recent Developments/Updates
Table 92. Jubilant Pharma Competitive Strengths & Weaknesses
Table 93. Novartis Basic Information, Manufacturing Base and Competitors
Table 94. Novartis Major Business
Table 95. Novartis SPECT and PET Diagnosis Radiopharmaceuticals Product and Services
Table 96. Novartis SPECT and PET Diagnosis Radiopharmaceuticals Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 97. Novartis Recent Developments/Updates
Table 98. Novartis Competitive Strengths & Weaknesses
Table 99. Curium Pharma Basic Information, Manufacturing Base and Competitors
Table 100. Curium Pharma Major Business
Table 101. Curium Pharma SPECT and PET Diagnosis Radiopharmaceuticals Product and Services
Table 102. Curium Pharma SPECT and PET Diagnosis Radiopharmaceuticals Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 103. Curium Pharma Recent Developments/Updates
Table 104. Curium Pharma Competitive Strengths & Weaknesses
Table 105. SIEMENS Basic Information, Manufacturing Base and Competitors
Table 106. SIEMENS Major Business
Table 107. SIEMENS SPECT and PET Diagnosis Radiopharmaceuticals Product and Services
Table 108. SIEMENS SPECT and PET Diagnosis Radiopharmaceuticals Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 109. SIEMENS Recent Developments/Updates
Table 110. SIEMENS Competitive Strengths & Weaknesses
Table 111. Lantheus Basic Information, Manufacturing Base and Competitors
Table 112. Lantheus Major Business
Table 113. Lantheus SPECT and PET Diagnosis Radiopharmaceuticals Product and Services
Table 114. Lantheus SPECT and PET Diagnosis Radiopharmaceuticals Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 115. Lantheus Recent Developments/Updates
Table 116. Lantheus Competitive Strengths & Weaknesses
Table 117. Bracco Imaging Basic Information, Manufacturing Base and Competitors
Table 118. Bracco Imaging Major Business
Table 119. Bracco Imaging SPECT and PET Diagnosis Radiopharmaceuticals Product and Services
Table 120. Bracco Imaging SPECT and PET Diagnosis Radiopharmaceuticals Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 121. Bracco Imaging Recent Developments/Updates
Table 122. Bracco Imaging Competitive Strengths & Weaknesses
Table 123. Eli Lilly Basic Information, Manufacturing Base and Competitors
Table 124. Eli Lilly Major Business
Table 125. Eli Lilly SPECT and PET Diagnosis Radiopharmaceuticals Product and Services
Table 126. Eli Lilly SPECT and PET Diagnosis Radiopharmaceuticals Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 127. Eli Lilly Recent Developments/Updates
Table 128. Eli Lilly Competitive Strengths & Weaknesses
Table 129. China Isotope & Radiation Basic Information, Manufacturing Base and Competitors
Table 130. China Isotope & Radiation Major Business
Table 131. China Isotope & Radiation SPECT and PET Diagnosis Radiopharmaceuticals Product and Services
Table 132. China Isotope & Radiation SPECT and PET Diagnosis Radiopharmaceuticals Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 133. China Isotope & Radiation Recent Developments/Updates
Table 134. China Isotope & Radiation Competitive Strengths & Weaknesses
Table 135. Dongcheng Basic Information, Manufacturing Base and Competitors
Table 136. Dongcheng Major Business
Table 137. Dongcheng SPECT and PET Diagnosis Radiopharmaceuticals Product and Services
Table 138. Dongcheng SPECT and PET Diagnosis Radiopharmaceuticals Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 139. Dongcheng Recent Developments/Updates
Table 140. Dongcheng Competitive Strengths & Weaknesses
Table 141. Global Key Players of SPECT and PET Diagnosis Radiopharmaceuticals Upstream (Raw Materials)
Table 142. Global SPECT and PET Diagnosis Radiopharmaceuticals Typical Customers
Table 143. SPECT and PET Diagnosis Radiopharmaceuticals Typical Distributors
Table 1. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value by Region (2021, 2025 and 2032) & (USD Million)
Table 2. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value by Region (2021-2026) & (USD Million)
Table 3. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value by Region (2027-2032) & (USD Million)
Table 4. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value Market Share by Region (2021-2026)
Table 5. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value Market Share by Region (2027-2032)
Table 6. World SPECT and PET Diagnosis Radiopharmaceuticals Production by Region (2021-2026) & (K Dose)
Table 7. World SPECT and PET Diagnosis Radiopharmaceuticals Production by Region (2027-2032) & (K Dose)
Table 8. World SPECT and PET Diagnosis Radiopharmaceuticals Production Market Share by Region (2021-2026)
Table 9. World SPECT and PET Diagnosis Radiopharmaceuticals Production Market Share by Region (2027-2032)
Table 10. World SPECT and PET Diagnosis Radiopharmaceuticals Average Price by Region (2021-2026) & (US$/Dose)
Table 11. World SPECT and PET Diagnosis Radiopharmaceuticals Average Price by Region (2027-2032) & (US$/Dose)
Table 12. SPECT and PET Diagnosis Radiopharmaceuticals Major Market Trends
Table 13. World SPECT and PET Diagnosis Radiopharmaceuticals Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (K Dose)
Table 14. World SPECT and PET Diagnosis Radiopharmaceuticals Consumption by Region (2021-2026) & (K Dose)
Table 15. World SPECT and PET Diagnosis Radiopharmaceuticals Consumption Forecast by Region (2027-2032) & (K Dose)
Table 16. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value by Manufacturer (2021-2026) & (USD Million)
Table 17. Production Value Market Share of Key SPECT and PET Diagnosis Radiopharmaceuticals Producers in 2025
Table 18. World SPECT and PET Diagnosis Radiopharmaceuticals Production by Manufacturer (2021-2026) & (K Dose)
Table 19. Production Market Share of Key SPECT and PET Diagnosis Radiopharmaceuticals Producers in 2025
Table 20. World SPECT and PET Diagnosis Radiopharmaceuticals Average Price by Manufacturer (2021-2026) & (US$/Dose)
Table 21. Global SPECT and PET Diagnosis Radiopharmaceuticals Company Evaluation Quadrant
Table 22. World SPECT and PET Diagnosis Radiopharmaceuticals Industry Rank of Major Manufacturers, Based on Production Value in 2025
Table 23. Head Office and SPECT and PET Diagnosis Radiopharmaceuticals Production Site of Key Manufacturer
Table 24. SPECT and PET Diagnosis Radiopharmaceuticals Market: Company Product Type Footprint
Table 25. SPECT and PET Diagnosis Radiopharmaceuticals Market: Company Product Application Footprint
Table 26. SPECT and PET Diagnosis Radiopharmaceuticals Competitive Factors
Table 27. SPECT and PET Diagnosis Radiopharmaceuticals New Entrant and Capacity Expansion Plans
Table 28. SPECT and PET Diagnosis Radiopharmaceuticals Mergers & Acquisitions Activity
Table 29. United States VS China SPECT and PET Diagnosis Radiopharmaceuticals Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 30. United States VS China SPECT and PET Diagnosis Radiopharmaceuticals Production Comparison, (2021 & 2025 & 2032) & (K Dose)
Table 31. United States VS China SPECT and PET Diagnosis Radiopharmaceuticals Consumption Comparison, (2021 & 2025 & 2032) & (K Dose)
Table 32. United States Based SPECT and PET Diagnosis Radiopharmaceuticals Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers SPECT and PET Diagnosis Radiopharmaceuticals Production Value, (2021-2026) & (USD Million)
Table 34. United States Based Manufacturers SPECT and PET Diagnosis Radiopharmaceuticals Production Value Market Share (2021-2026)
Table 35. United States Based Manufacturers SPECT and PET Diagnosis Radiopharmaceuticals Production (2021-2026) & (K Dose)
Table 36. United States Based Manufacturers SPECT and PET Diagnosis Radiopharmaceuticals Production Market Share (2021-2026)
Table 37. China Based SPECT and PET Diagnosis Radiopharmaceuticals Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers SPECT and PET Diagnosis Radiopharmaceuticals Production Value, (2021-2026) & (USD Million)
Table 39. China Based Manufacturers SPECT and PET Diagnosis Radiopharmaceuticals Production Value Market Share (2021-2026)
Table 40. China Based Manufacturers SPECT and PET Diagnosis Radiopharmaceuticals Production, (2021-2026) & (K Dose)
Table 41. China Based Manufacturers SPECT and PET Diagnosis Radiopharmaceuticals Production Market Share (2021-2026)
Table 42. Rest of World Based SPECT and PET Diagnosis Radiopharmaceuticals Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers SPECT and PET Diagnosis Radiopharmaceuticals Production Value, (2021-2026) & (USD Million)
Table 44. Rest of World Based Manufacturers SPECT and PET Diagnosis Radiopharmaceuticals Production Value Market Share (2021-2026)
Table 45. Rest of World Based Manufacturers SPECT and PET Diagnosis Radiopharmaceuticals Production, (2021-2026) & (K Dose)
Table 46. Rest of World Based Manufacturers SPECT and PET Diagnosis Radiopharmaceuticals Production Market Share (2021-2026)
Table 47. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value by Type, (USD Million), 2021 & 2025 & 2032
Table 48. World SPECT and PET Diagnosis Radiopharmaceuticals Production by Type (2021-2026) & (K Dose)
Table 49. World SPECT and PET Diagnosis Radiopharmaceuticals Production by Type (2027-2032) & (K Dose)
Table 50. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value by Type (2021-2026) & (USD Million)
Table 51. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value by Type (2027-2032) & (USD Million)
Table 52. World SPECT and PET Diagnosis Radiopharmaceuticals Average Price by Type (2021-2026) & (US$/Dose)
Table 53. World SPECT and PET Diagnosis Radiopharmaceuticals Average Price by Type (2027-2032) & (US$/Dose)
Table 54. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value by Imaging Modality, (USD Million), 2021 & 2025 & 2032
Table 55. World SPECT and PET Diagnosis Radiopharmaceuticals Production by Imaging Modality (2021-2026) & (K Dose)
Table 56. World SPECT and PET Diagnosis Radiopharmaceuticals Production by Imaging Modality (2027-2032) & (K Dose)
Table 57. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value by Imaging Modality (2021-2026) & (USD Million)
Table 58. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value by Imaging Modality (2027-2032) & (USD Million)
Table 59. World SPECT and PET Diagnosis Radiopharmaceuticals Average Price by Imaging Modality (2021-2026) & (US$/Dose)
Table 60. World SPECT and PET Diagnosis Radiopharmaceuticals Average Price by Imaging Modality (2027-2032) & (US$/Dose)
Table 61. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value by End User, (USD Million), 2021 & 2025 & 2032
Table 62. World SPECT and PET Diagnosis Radiopharmaceuticals Production by End User (2021-2026) & (K Dose)
Table 63. World SPECT and PET Diagnosis Radiopharmaceuticals Production by End User (2027-2032) & (K Dose)
Table 64. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value by End User (2021-2026) & (USD Million)
Table 65. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value by End User (2027-2032) & (USD Million)
Table 66. World SPECT and PET Diagnosis Radiopharmaceuticals Average Price by End User (2021-2026) & (US$/Dose)
Table 67. World SPECT and PET Diagnosis Radiopharmaceuticals Average Price by End User (2027-2032) & (US$/Dose)
Table 68. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value by Application, (USD Million), 2021 & 2025 & 2032
Table 69. World SPECT and PET Diagnosis Radiopharmaceuticals Production by Application (2021-2026) & (K Dose)
Table 70. World SPECT and PET Diagnosis Radiopharmaceuticals Production by Application (2027-2032) & (K Dose)
Table 71. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value by Application (2021-2026) & (USD Million)
Table 72. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value by Application (2027-2032) & (USD Million)
Table 73. World SPECT and PET Diagnosis Radiopharmaceuticals Average Price by Application (2021-2026) & (US$/Dose)
Table 74. World SPECT and PET Diagnosis Radiopharmaceuticals Average Price by Application (2027-2032) & (US$/Dose)
Table 75. Cardinal Health Basic Information, Manufacturing Base and Competitors
Table 76. Cardinal Health Major Business
Table 77. Cardinal Health SPECT and PET Diagnosis Radiopharmaceuticals Product and Services
Table 78. Cardinal Health SPECT and PET Diagnosis Radiopharmaceuticals Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 79. Cardinal Health Recent Developments/Updates
Table 80. Cardinal Health Competitive Strengths & Weaknesses
Table 81. GE Healthcare Basic Information, Manufacturing Base and Competitors
Table 82. GE Healthcare Major Business
Table 83. GE Healthcare SPECT and PET Diagnosis Radiopharmaceuticals Product and Services
Table 84. GE Healthcare SPECT and PET Diagnosis Radiopharmaceuticals Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 85. GE Healthcare Recent Developments/Updates
Table 86. GE Healthcare Competitive Strengths & Weaknesses
Table 87. Jubilant Pharma Basic Information, Manufacturing Base and Competitors
Table 88. Jubilant Pharma Major Business
Table 89. Jubilant Pharma SPECT and PET Diagnosis Radiopharmaceuticals Product and Services
Table 90. Jubilant Pharma SPECT and PET Diagnosis Radiopharmaceuticals Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 91. Jubilant Pharma Recent Developments/Updates
Table 92. Jubilant Pharma Competitive Strengths & Weaknesses
Table 93. Novartis Basic Information, Manufacturing Base and Competitors
Table 94. Novartis Major Business
Table 95. Novartis SPECT and PET Diagnosis Radiopharmaceuticals Product and Services
Table 96. Novartis SPECT and PET Diagnosis Radiopharmaceuticals Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 97. Novartis Recent Developments/Updates
Table 98. Novartis Competitive Strengths & Weaknesses
Table 99. Curium Pharma Basic Information, Manufacturing Base and Competitors
Table 100. Curium Pharma Major Business
Table 101. Curium Pharma SPECT and PET Diagnosis Radiopharmaceuticals Product and Services
Table 102. Curium Pharma SPECT and PET Diagnosis Radiopharmaceuticals Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 103. Curium Pharma Recent Developments/Updates
Table 104. Curium Pharma Competitive Strengths & Weaknesses
Table 105. SIEMENS Basic Information, Manufacturing Base and Competitors
Table 106. SIEMENS Major Business
Table 107. SIEMENS SPECT and PET Diagnosis Radiopharmaceuticals Product and Services
Table 108. SIEMENS SPECT and PET Diagnosis Radiopharmaceuticals Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 109. SIEMENS Recent Developments/Updates
Table 110. SIEMENS Competitive Strengths & Weaknesses
Table 111. Lantheus Basic Information, Manufacturing Base and Competitors
Table 112. Lantheus Major Business
Table 113. Lantheus SPECT and PET Diagnosis Radiopharmaceuticals Product and Services
Table 114. Lantheus SPECT and PET Diagnosis Radiopharmaceuticals Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 115. Lantheus Recent Developments/Updates
Table 116. Lantheus Competitive Strengths & Weaknesses
Table 117. Bracco Imaging Basic Information, Manufacturing Base and Competitors
Table 118. Bracco Imaging Major Business
Table 119. Bracco Imaging SPECT and PET Diagnosis Radiopharmaceuticals Product and Services
Table 120. Bracco Imaging SPECT and PET Diagnosis Radiopharmaceuticals Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 121. Bracco Imaging Recent Developments/Updates
Table 122. Bracco Imaging Competitive Strengths & Weaknesses
Table 123. Eli Lilly Basic Information, Manufacturing Base and Competitors
Table 124. Eli Lilly Major Business
Table 125. Eli Lilly SPECT and PET Diagnosis Radiopharmaceuticals Product and Services
Table 126. Eli Lilly SPECT and PET Diagnosis Radiopharmaceuticals Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 127. Eli Lilly Recent Developments/Updates
Table 128. Eli Lilly Competitive Strengths & Weaknesses
Table 129. China Isotope & Radiation Basic Information, Manufacturing Base and Competitors
Table 130. China Isotope & Radiation Major Business
Table 131. China Isotope & Radiation SPECT and PET Diagnosis Radiopharmaceuticals Product and Services
Table 132. China Isotope & Radiation SPECT and PET Diagnosis Radiopharmaceuticals Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 133. China Isotope & Radiation Recent Developments/Updates
Table 134. China Isotope & Radiation Competitive Strengths & Weaknesses
Table 135. Dongcheng Basic Information, Manufacturing Base and Competitors
Table 136. Dongcheng Major Business
Table 137. Dongcheng SPECT and PET Diagnosis Radiopharmaceuticals Product and Services
Table 138. Dongcheng SPECT and PET Diagnosis Radiopharmaceuticals Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 139. Dongcheng Recent Developments/Updates
Table 140. Dongcheng Competitive Strengths & Weaknesses
Table 141. Global Key Players of SPECT and PET Diagnosis Radiopharmaceuticals Upstream (Raw Materials)
Table 142. Global SPECT and PET Diagnosis Radiopharmaceuticals Typical Customers
Table 143. SPECT and PET Diagnosis Radiopharmaceuticals Typical Distributors
LIST OF FIGURES
Figure 1. SPECT and PET Diagnosis Radiopharmaceuticals Picture
Figure 2. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value: 2021 & 2025 & 2032, (USD Million)
Figure 3. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value and Forecast (2021-2032) & (USD Million)
Figure 4. World SPECT and PET Diagnosis Radiopharmaceuticals Production (2021-2032) & (K Dose)
Figure 5. World SPECT and PET Diagnosis Radiopharmaceuticals Average Price (2021-2032) & (US$/Dose)
Figure 6. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value Market Share by Region (2021-2032)
Figure 7. World SPECT and PET Diagnosis Radiopharmaceuticals Production Market Share by Region (2021-2032)
Figure 8. North America SPECT and PET Diagnosis Radiopharmaceuticals Production (2021-2032) & (K Dose)
Figure 9. Europe SPECT and PET Diagnosis Radiopharmaceuticals Production (2021-2032) & (K Dose)
Figure 10. China SPECT and PET Diagnosis Radiopharmaceuticals Production (2021-2032) & (K Dose)
Figure 11. Japan SPECT and PET Diagnosis Radiopharmaceuticals Production (2021-2032) & (K Dose)
Figure 12. SPECT and PET Diagnosis Radiopharmaceuticals Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World SPECT and PET Diagnosis Radiopharmaceuticals Consumption (2021-2032) & (K Dose)
Figure 15. World SPECT and PET Diagnosis Radiopharmaceuticals Consumption Market Share by Region (2021-2032)
Figure 16. United States SPECT and PET Diagnosis Radiopharmaceuticals Consumption (2021-2032) & (K Dose)
Figure 17. China SPECT and PET Diagnosis Radiopharmaceuticals Consumption (2021-2032) & (K Dose)
Figure 18. Europe SPECT and PET Diagnosis Radiopharmaceuticals Consumption (2021-2032) & (K Dose)
Figure 19. Japan SPECT and PET Diagnosis Radiopharmaceuticals Consumption (2021-2032) & (K Dose)
Figure 20. South Korea SPECT and PET Diagnosis Radiopharmaceuticals Consumption (2021-2032) & (K Dose)
Figure 21. ASEAN SPECT and PET Diagnosis Radiopharmaceuticals Consumption (2021-2032) & (K Dose)
Figure 22. India SPECT and PET Diagnosis Radiopharmaceuticals Consumption (2021-2032) & (K Dose)
Figure 23. Producer Shipments of SPECT and PET Diagnosis Radiopharmaceuticals by Manufacturer Revenue ($MM) and Market Share (%): 2025
Figure 24. Global Four-firm Concentration Ratios (CR4) for SPECT and PET Diagnosis Radiopharmaceuticals Markets in 2025
Figure 25. Global Four-firm Concentration Ratios (CR8) for SPECT and PET Diagnosis Radiopharmaceuticals Markets in 2025
Figure 26. United States VS China: SPECT and PET Diagnosis Radiopharmaceuticals Production Value Market Share Comparison (2021 & 2025 & 2032)
Figure 27. United States VS China: SPECT and PET Diagnosis Radiopharmaceuticals Production Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: SPECT and PET Diagnosis Radiopharmaceuticals Consumption Market Share Comparison (2021 & 2025 & 2032)
Figure 29. United States Based Manufacturers SPECT and PET Diagnosis Radiopharmaceuticals Production Market Share 2025
Figure 30. China Based Manufacturers SPECT and PET Diagnosis Radiopharmaceuticals Production Market Share 2025
Figure 31. Rest of World Based Manufacturers SPECT and PET Diagnosis Radiopharmaceuticals Production Market Share 2025
Figure 32. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 33. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value Market Share by Type in 2025
Figure 34. Technetium 99
Figure 35. Fluorine 18
Figure 36. Other
Figure 37. World SPECT and PET Diagnosis Radiopharmaceuticals Production Market Share by Type (2021-2032)
Figure 38. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value Market Share by Type (2021-2032)
Figure 39. World SPECT and PET Diagnosis Radiopharmaceuticals Average Price by Type (2021-2032) & (US$/Dose)
Figure 40. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value by Imaging Modality, (USD Million), 2021 & 2025 & 2032
Figure 41. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value Market Share by Imaging Modality in 2025
Figure 42. PET Imaging
Figure 43. SPECT Imaging
Figure 44. World SPECT and PET Diagnosis Radiopharmaceuticals Production Market Share by Imaging Modality (2021-2032)
Figure 45. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value Market Share by Imaging Modality (2021-2032)
Figure 46. World SPECT and PET Diagnosis Radiopharmaceuticals Average Price by Imaging Modality (2021-2032) & (US$/Dose)
Figure 47. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value by End User, (USD Million), 2021 & 2025 & 2032
Figure 48. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value Market Share by End User in 2025
Figure 49. Hospitals
Figure 50. Imaging Centers
Figure 51. Other
Figure 52. World SPECT and PET Diagnosis Radiopharmaceuticals Production Market Share by End User (2021-2032)
Figure 53. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value Market Share by End User (2021-2032)
Figure 54. World SPECT and PET Diagnosis Radiopharmaceuticals Average Price by End User (2021-2032) & (US$/Dose)
Figure 55. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 56. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value Market Share by Application in 2025
Figure 57. Oncology
Figure 58. Cardiology
Figure 59. Other
Figure 60. World SPECT and PET Diagnosis Radiopharmaceuticals Production Market Share by Application (2021-2032)
Figure 61. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value Market Share by Application (2021-2032)
Figure 62. World SPECT and PET Diagnosis Radiopharmaceuticals Average Price by Application (2021-2032) & (US$/Dose)
Figure 63. SPECT and PET Diagnosis Radiopharmaceuticals Industry Chain
Figure 64. SPECT and PET Diagnosis Radiopharmaceuticals Procurement Model
Figure 65. SPECT and PET Diagnosis Radiopharmaceuticals Sales Model
Figure 66. SPECT and PET Diagnosis Radiopharmaceuticals Sales Channels, Direct Sales, and Distribution
Figure 67. Methodology
Figure 68. Research Process and Data Source
Figure 1. SPECT and PET Diagnosis Radiopharmaceuticals Picture
Figure 2. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value: 2021 & 2025 & 2032, (USD Million)
Figure 3. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value and Forecast (2021-2032) & (USD Million)
Figure 4. World SPECT and PET Diagnosis Radiopharmaceuticals Production (2021-2032) & (K Dose)
Figure 5. World SPECT and PET Diagnosis Radiopharmaceuticals Average Price (2021-2032) & (US$/Dose)
Figure 6. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value Market Share by Region (2021-2032)
Figure 7. World SPECT and PET Diagnosis Radiopharmaceuticals Production Market Share by Region (2021-2032)
Figure 8. North America SPECT and PET Diagnosis Radiopharmaceuticals Production (2021-2032) & (K Dose)
Figure 9. Europe SPECT and PET Diagnosis Radiopharmaceuticals Production (2021-2032) & (K Dose)
Figure 10. China SPECT and PET Diagnosis Radiopharmaceuticals Production (2021-2032) & (K Dose)
Figure 11. Japan SPECT and PET Diagnosis Radiopharmaceuticals Production (2021-2032) & (K Dose)
Figure 12. SPECT and PET Diagnosis Radiopharmaceuticals Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World SPECT and PET Diagnosis Radiopharmaceuticals Consumption (2021-2032) & (K Dose)
Figure 15. World SPECT and PET Diagnosis Radiopharmaceuticals Consumption Market Share by Region (2021-2032)
Figure 16. United States SPECT and PET Diagnosis Radiopharmaceuticals Consumption (2021-2032) & (K Dose)
Figure 17. China SPECT and PET Diagnosis Radiopharmaceuticals Consumption (2021-2032) & (K Dose)
Figure 18. Europe SPECT and PET Diagnosis Radiopharmaceuticals Consumption (2021-2032) & (K Dose)
Figure 19. Japan SPECT and PET Diagnosis Radiopharmaceuticals Consumption (2021-2032) & (K Dose)
Figure 20. South Korea SPECT and PET Diagnosis Radiopharmaceuticals Consumption (2021-2032) & (K Dose)
Figure 21. ASEAN SPECT and PET Diagnosis Radiopharmaceuticals Consumption (2021-2032) & (K Dose)
Figure 22. India SPECT and PET Diagnosis Radiopharmaceuticals Consumption (2021-2032) & (K Dose)
Figure 23. Producer Shipments of SPECT and PET Diagnosis Radiopharmaceuticals by Manufacturer Revenue ($MM) and Market Share (%): 2025
Figure 24. Global Four-firm Concentration Ratios (CR4) for SPECT and PET Diagnosis Radiopharmaceuticals Markets in 2025
Figure 25. Global Four-firm Concentration Ratios (CR8) for SPECT and PET Diagnosis Radiopharmaceuticals Markets in 2025
Figure 26. United States VS China: SPECT and PET Diagnosis Radiopharmaceuticals Production Value Market Share Comparison (2021 & 2025 & 2032)
Figure 27. United States VS China: SPECT and PET Diagnosis Radiopharmaceuticals Production Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: SPECT and PET Diagnosis Radiopharmaceuticals Consumption Market Share Comparison (2021 & 2025 & 2032)
Figure 29. United States Based Manufacturers SPECT and PET Diagnosis Radiopharmaceuticals Production Market Share 2025
Figure 30. China Based Manufacturers SPECT and PET Diagnosis Radiopharmaceuticals Production Market Share 2025
Figure 31. Rest of World Based Manufacturers SPECT and PET Diagnosis Radiopharmaceuticals Production Market Share 2025
Figure 32. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 33. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value Market Share by Type in 2025
Figure 34. Technetium 99
Figure 35. Fluorine 18
Figure 36. Other
Figure 37. World SPECT and PET Diagnosis Radiopharmaceuticals Production Market Share by Type (2021-2032)
Figure 38. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value Market Share by Type (2021-2032)
Figure 39. World SPECT and PET Diagnosis Radiopharmaceuticals Average Price by Type (2021-2032) & (US$/Dose)
Figure 40. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value by Imaging Modality, (USD Million), 2021 & 2025 & 2032
Figure 41. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value Market Share by Imaging Modality in 2025
Figure 42. PET Imaging
Figure 43. SPECT Imaging
Figure 44. World SPECT and PET Diagnosis Radiopharmaceuticals Production Market Share by Imaging Modality (2021-2032)
Figure 45. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value Market Share by Imaging Modality (2021-2032)
Figure 46. World SPECT and PET Diagnosis Radiopharmaceuticals Average Price by Imaging Modality (2021-2032) & (US$/Dose)
Figure 47. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value by End User, (USD Million), 2021 & 2025 & 2032
Figure 48. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value Market Share by End User in 2025
Figure 49. Hospitals
Figure 50. Imaging Centers
Figure 51. Other
Figure 52. World SPECT and PET Diagnosis Radiopharmaceuticals Production Market Share by End User (2021-2032)
Figure 53. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value Market Share by End User (2021-2032)
Figure 54. World SPECT and PET Diagnosis Radiopharmaceuticals Average Price by End User (2021-2032) & (US$/Dose)
Figure 55. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 56. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value Market Share by Application in 2025
Figure 57. Oncology
Figure 58. Cardiology
Figure 59. Other
Figure 60. World SPECT and PET Diagnosis Radiopharmaceuticals Production Market Share by Application (2021-2032)
Figure 61. World SPECT and PET Diagnosis Radiopharmaceuticals Production Value Market Share by Application (2021-2032)
Figure 62. World SPECT and PET Diagnosis Radiopharmaceuticals Average Price by Application (2021-2032) & (US$/Dose)
Figure 63. SPECT and PET Diagnosis Radiopharmaceuticals Industry Chain
Figure 64. SPECT and PET Diagnosis Radiopharmaceuticals Procurement Model
Figure 65. SPECT and PET Diagnosis Radiopharmaceuticals Sales Model
Figure 66. SPECT and PET Diagnosis Radiopharmaceuticals Sales Channels, Direct Sales, and Distribution
Figure 67. Methodology
Figure 68. Research Process and Data Source
